# A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

> **NCT02122913** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 75 (actual)

## Conditions studied

- Solid Tumors Harboring NTRK Fusion

## Interventions

- **DRUG:** Larotrectinib (Vitrakvi, BAY2757556)

## Key facts

- **NCT ID:** NCT02122913
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-04
- **Primary completion:** 2017-02-01
- **Final completion:** 2021-04-09
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02122913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02122913, "A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02122913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*